Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Double chin

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

- PMLiVE

Incisionless device to transform diabetes, liver disease and severe obesity treatment

ForePass replicates common invasive metabolic surgeries without making any incisions

Bayer symbol

Bayer’s non-hormonal menopause drug elinzanetant shows promise in phase 3 studies

Vasomotor symptoms are estimated to affect up to 80% of menopausal women

- PMLiVE

Novo Nordisk announces two new research collaborations for cardiometabolic diseases

The research programmes will develop novel treatments for obesity and MASH

- PMLiVE

Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn

The company will gain access to a portfolio of incretin-based therapies for diabetes and obesity

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

- PMLiVE

Novo Nordisk acquires Embark Biotech in deal worth over €470m

Novo gains access to Embark's lead asset targeting obesity and other cardiometabolic diseases

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Eli Lilly to acquire Versanis in deal worth over $1.9bn

The deal marks a significant boost to the company’s cardiometabolic disease pipeline

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links